These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36198460)

  • 41. Estimated impact and cost-effectiveness of rotavirus vaccination in Senegal: A country-led analysis.
    Diop A; Atherly D; Faye A; Lamine Sall F; Clark AD; Nadiel L; Yade B; Ndiaye M; Fafa Cissé M; Ba M
    Vaccine; 2015 May; 33 Suppl 1():A119-25. PubMed ID: 25919151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thresholds for decision-making: informing the cost-effectiveness and affordability of rotavirus vaccines in Malaysia.
    Loganathan T; Ng CW; Lee WS; Hutubessy RCW; Verguet S; Jit M
    Health Policy Plan; 2018 Mar; 33(2):204-214. PubMed ID: 29228339
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cost-effectiveness of rotavirus vaccination in Ghana: Examining impacts from 2012 to 2031.
    Nonvignon J; Atherly D; Pecenka C; Aikins M; Gazley L; Groman D; Narh CT; Armah G
    Vaccine; 2018 Nov; 36(47):7215-7221. PubMed ID: 29223486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease.
    Glass RI; Tate JE; Jiang B; Parashar U
    J Infect Dis; 2021 Sep; 224(12 Suppl 2):S331-S342. PubMed ID: 34590142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Nigeria.
    Anderson JD; Pecenka CJ; Bagamian KH; Rheingans RD
    PLoS One; 2020; 15(5):e0232941. PubMed ID: 32469927
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of rotavirus vaccination in China: Projected possibility of scale-up from the current domestic option.
    Cui S; Tobe RG; Mo X; Liu X; Xu L; Li S
    BMC Infect Dis; 2016 Nov; 16(1):677. PubMed ID: 27846803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost effectiveness evaluation of a rotavirus vaccination program in Argentina.
    Martí SG; Alcaraz A; Valanzasca P; McMullen M; Standaert B; Garay U; Lepetic A; Gomez J
    Vaccine; 2015 Oct; 33(42):5684-5690. PubMed ID: 26303875
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An overview of rotavirus vaccination programs in developing countries.
    Hallowell BD; Tate J; Parashar U
    Expert Rev Vaccines; 2020 Jun; 19(6):529-537. PubMed ID: 32543239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epidemiological and Economic Impact of Monovalent and Pentavalent Rotavirus Vaccines in Low and Middle Income Countries: A Cost-effectiveness Modeling Analysis.
    Paternina-Caicedo A; De la Hoz-Restrepo F; Alvis-Guzmán N
    Pediatr Infect Dis J; 2015 Jul; 34(7):e176-84. PubMed ID: 25923424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Socio-economic modelling of rotavirus vaccination in Castilla y Leon, Spain.
    Pérez-Rubio A; Luquero FJ; Eiros Bouza JM; Castrodeza Sanz JJ; Bachiller Luque MR; de Lejarazu RO; Sánchez Porto A
    Infez Med; 2011 Sep; 19(3):166-75. PubMed ID: 22037437
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity and safety of two monovalent rotavirus vaccines, ROTAVAC® and ROTAVAC 5D® in Zambian infants.
    Chilengi R; Mwila-Kazimbaya K; Chirwa M; Sukwa N; Chipeta C; Velu RM; Katanekwa N; Babji S; Kang G; McNeal MM; Meyer N; Gompana G; Hazra S; Tang Y; Flores J; Bhat N; Rathi N
    Vaccine; 2021 Jun; 39(27):3633-3640. PubMed ID: 33992437
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK.
    Martin A; Batty A; Roberts JA; Standaert B
    Vaccine; 2009 Jul; 27(33):4520-8. PubMed ID: 19446594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diversity of rotavirus genotypes circulating in children < 5 years of age hospitalized for acute gastroenteritis in India from 2005 to 2016: analysis of temporal and regional genotype variation.
    Giri S; Kumar CPG; Khakha SA; Chawla-Sarkar M; Gopalkrishna V; Chitambar SD; Ray P; Venkatasubramanian S; Borkakoty BJ; Roy S; Bhat J; Dwibedi B; Das P; Paluru V; Ramani S; Babji S; Arora R; Mehendale SM; Gupte MD; Kang G;
    BMC Infect Dis; 2020 Oct; 20(1):740. PubMed ID: 33036575
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review of Over 15 Years Postmarketing Safety Surveillance Spontaneous Data for the Human Rotavirus Vaccine (Rotarix) on Intussusception.
    Singh T; Delannois F; Haguinet F; Molo LY
    Drug Saf; 2022 Feb; 45(2):155-168. PubMed ID: 35015268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness estimates of vaccination against rotavirus in Piedmont, Italy.
    Gualano MR; Thomas R; Gili R; Scaioli G; Voglino G; Zotti C
    J Infect Public Health; 2018; 11(6):867-872. PubMed ID: 30078657
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of diarrhoea associated rotavirus and co-infection with diarrhoeagenic pathogens in the Littoral region of Cameroon using ELISA, RT-PCR and Luminex xTAG GPP assays.
    Ghapoutsa RN; Boda M; Gautam R; Ndze VN; Mugyia AE; Etoa FX; Bowen MD; Esona MD
    BMC Infect Dis; 2021 Jun; 21(1):614. PubMed ID: 34182936
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Health impact and cost-effectiveness of a domestically-produced rotavirus vaccine in India: A model based analysis.
    Rose J; Homa L; Meropol SB; Debanne SM; Bielefeld R; Hoyen C; Singer ME
    PLoS One; 2017; 12(11):e0187446. PubMed ID: 29099848
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost-effectiveness of rotavirus vaccination in Australia.
    Newall AT; Beutels P; Macartney K; Wood J; MacIntyre CR
    Vaccine; 2007 Dec; 25(52):8851-60. PubMed ID: 18022735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cost-Effectiveness of Rotavirus Vaccination in France-Accounting for Indirect Protection.
    Yamin D; Atkins KE; Remy V; Galvani AP
    Value Health; 2016; 19(6):811-819. PubMed ID: 27712709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.